CR20200033A - Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas - Google Patents
Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosasInfo
- Publication number
- CR20200033A CR20200033A CR20200033A CR20200033A CR20200033A CR 20200033 A CR20200033 A CR 20200033A CR 20200033 A CR20200033 A CR 20200033A CR 20200033 A CR20200033 A CR 20200033A CR 20200033 A CR20200033 A CR 20200033A
- Authority
- CR
- Costa Rica
- Prior art keywords
- mitoketoscins
- mitochondrial
- cancer cells
- methods
- based therapeutics
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/14—Libraries containing macromolecular compounds and not covered by groups C40B40/06 - C40B40/12
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Oncology (AREA)
- Theoretical Computer Science (AREA)
- Computing Systems (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Communicable Diseases (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Indole Compounds (AREA)
Abstract
La presente descripción se refiere a compuestos que se enlazan a por lo menos una de ACAT1/2 y OXCT1/2 e inhiben la producción mitocondrial de ATP, referidos en este documento como mitocetoscinas. Se dan a conocer métodos de prospección de compuestos por la inhibición mitocondrial y propiedades anticancerosas. También se describen métodos para usar mitocetoscinas para prevenir o tratar cáncer, infecciones bacterianas y levadura patógena, así como también métodos para usar mitocetoscinas para proporcionar beneficios anti-envejecimiento. También se dan a conocer compuestos de mitocetoscina específicos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762524829P | 2017-06-26 | 2017-06-26 | |
| PCT/US2018/039354 WO2019005698A1 (en) | 2017-06-26 | 2018-06-25 | MITOCETOSCINES: MITOCHONDRIAL THERAPEUTIC AGENTS TARGETING THE METABOLISM OF KETONES IN CANCER CELLS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200033A true CR20200033A (es) | 2020-03-05 |
Family
ID=64742979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200033A CR20200033A (es) | 2017-06-26 | 2018-06-25 | Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11667639B2 (es) |
| EP (1) | EP3644988B1 (es) |
| JP (1) | JP7397672B2 (es) |
| KR (2) | KR102646172B1 (es) |
| CN (1) | CN110913854B (es) |
| AU (2) | AU2018292283B2 (es) |
| CA (1) | CA3064452A1 (es) |
| CL (1) | CL2019003708A1 (es) |
| CO (1) | CO2019014259A2 (es) |
| CR (1) | CR20200033A (es) |
| CU (1) | CU20190106A7 (es) |
| DO (2) | DOP2019000312A (es) |
| EC (1) | ECSP20001729A (es) |
| IL (2) | IL292109B2 (es) |
| MX (1) | MX2019014806A (es) |
| PE (2) | PE20200295A1 (es) |
| PH (1) | PH12019502892A1 (es) |
| RU (1) | RU2020102908A (es) |
| SG (1) | SG11201913134UA (es) |
| WO (1) | WO2019005698A1 (es) |
| ZA (2) | ZA201907831B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3064452A1 (en) * | 2017-06-26 | 2019-01-03 | Lunella Biotech, Inc. | Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells |
| CA3078791A1 (en) | 2017-10-11 | 2019-04-18 | Lunella Biotech, Inc. | Anti-mitochondrial inhibitors for oncogenic ras and myc |
| SG11202003739SA (en) * | 2017-11-03 | 2020-05-28 | Bioimics Ab | Anti-infective heterocyclic compounds and uses thereof |
| WO2019232161A1 (en) | 2018-06-01 | 2019-12-05 | Lunella Biotech, Inc. | Biomarkers and therapeutics for endocrine therapy resistance |
| PE20211006A1 (es) | 2018-10-02 | 2021-06-01 | Lunella Biotech Inc | Derivados de azitromicina y roxitromicina como farmacos senoliticos |
| EP3976197B1 (en) | 2019-05-24 | 2025-07-16 | Lunella Biotech, Inc. | Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3517067A (en) | 1964-02-11 | 1970-06-23 | Eastman Kodak Co | Syntheses of quaternary phosphonium salts |
| EP0310361A3 (en) | 1987-09-30 | 1989-05-24 | Beckman Instruments, Inc. | Tridentate conjugate and method of use thereof |
| SI9011409A (en) | 1990-07-18 | 1995-10-31 | Pliva Pharm & Chem Works | O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them |
| FR2674522B1 (fr) | 1991-03-26 | 1993-07-16 | Lipha | Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant. |
| EP0656422B1 (en) | 1993-11-05 | 2000-04-26 | Amersham Pharmacia Biotech UK Limited | Chloramphenicol acetyl transferase (CAT) assay |
| WO1995015770A1 (en) | 1993-12-09 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
| US5441939A (en) | 1994-03-04 | 1995-08-15 | Pfizer Inc. | 3"-desmethoxy derivatives of erythromycin and azithromycin |
| CA2189001A1 (en) | 1994-04-26 | 1995-11-02 | Nobuhiro Narita | Medicinal composition as a remedy for nonsmall cell lung cancer |
| CA2219277A1 (en) | 1995-05-03 | 1996-11-07 | Pfizer Limited | Novel tetracycline derivatives |
| JP4590523B2 (ja) | 1997-11-25 | 2010-12-01 | アンティポディーン ファーマシューティカルズ インコーポレイテッド | ミトコンドリアを標的とする抗酸化剤 |
| DK0941998T3 (da) | 1998-03-03 | 2004-09-20 | Pfizer Prod Inc | 3,6-ketalmakrolidantibiotika |
| AUPP437698A0 (en) | 1998-06-30 | 1998-07-23 | Baumgart, Karl | Methods for treatment of coronary, carotid and other vascular disease |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US7485298B2 (en) | 2002-05-23 | 2009-02-03 | Michael Powell | Diagnosis and treatment of human dormancy-related sequellae |
| EP2517729A3 (en) | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
| TWI324600B (en) | 2003-07-07 | 2010-05-11 | Kowa Co | 2,4-bis (trifluoroethoxy) pyridine compound and drug containing the compound |
| WO2005062851A2 (en) | 2003-12-22 | 2005-07-14 | Pappolla Miguel A | Indole-3-propionamide and derivatives thereof |
| CA2557215A1 (en) | 2004-02-26 | 2005-09-09 | Advanced Ocular Systems Limited | Tetracycline derivatives for the treatment of ocular pathologies |
| US20060083727A1 (en) | 2004-07-15 | 2006-04-20 | Nanobac Pharmaceuticals, Inc. | Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation |
| TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
| ATE523519T1 (de) | 2005-01-14 | 2011-09-15 | Glaxo Group Ltd | Makrolidverbindungen mit biotin und fotoaffinitätsgruppe zur identifizierung eines makrolid-targets |
| CN101242822B (zh) | 2005-07-18 | 2011-08-24 | 彼帕科学公司 | 治疗卵巢癌的药物 |
| MX2008014953A (es) | 2006-05-26 | 2009-03-05 | Bayer Healthcare Llc | Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer. |
| JP2009539769A (ja) | 2006-06-02 | 2009-11-19 | アリアド ジーン セラピューティクス インコーポレイテッド | カペシタビン併用療法 |
| US20070292906A1 (en) | 2006-06-14 | 2007-12-20 | Bristol-Myers Squibb Company | Assay for measuring acyltransferase activity |
| MX2009004748A (es) | 2006-10-30 | 2009-08-25 | Southern Res Inst | Interaccion orientada nbs1-atm para sensibilizar celulas cancerosas a radioterapia y quimioterapia. |
| JP5933893B2 (ja) | 2006-12-14 | 2016-06-15 | アブラクシス バイオサイエンス， エルエルシー | ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法 |
| US8075902B2 (en) | 2007-01-03 | 2011-12-13 | Michael Powell | Diagnosis and treatment of cancer related to human dormancy |
| US8647673B2 (en) | 2007-07-24 | 2014-02-11 | Wayne State University | Nanoparticles for imaging and treating chlamydial infection |
| WO2009038656A1 (en) | 2007-09-17 | 2009-03-26 | Kosta Steliou | Mitochondria-targeting antioxidant therapeutics |
| CA2700257A1 (en) | 2007-10-02 | 2009-04-09 | Hartmut Land | Methods and compositions related to synergistic responses to oncogenic mutations |
| WO2010121177A2 (en) | 2009-04-17 | 2010-10-21 | Colby Pharmaceutical Company | Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses |
| CN102439453A (zh) | 2009-05-20 | 2012-05-02 | 日内瓦大学 | 癌症起始细胞的线粒体活性抑制剂及其用途 |
| HUE053793T2 (hu) | 2009-12-04 | 2021-07-28 | Oncoc4 Inc | Hipoxia indukálta faktor gátlók alkalmazásai |
| WO2011140047A1 (en) | 2010-05-04 | 2011-11-10 | Trustees Of Dartmouth College | Methods for identifying allosteric and other novel acyl-coenzyme a:cholesterol acyltransferase inhibitors |
| EP2606349A4 (en) * | 2010-08-20 | 2014-04-30 | Univ Jefferson | AGENTS FOR CANCER DIAGNOSIS AND CANCER THERAPY |
| US20120141467A1 (en) | 2010-12-03 | 2012-06-07 | Schneider Daniel J | Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma |
| US20130172430A1 (en) * | 2010-12-10 | 2013-07-04 | Michael P. Lisanti | Prognosis and treatment of breast cancer |
| EA032840B8 (ru) | 2011-06-22 | 2020-06-18 | Вайоми Терапеутикс Лимитед | Пролекарства на основе конъюгатов противогрибковых агентов и их применение |
| US10441577B2 (en) | 2011-07-08 | 2019-10-15 | Helmholtz Zentrum Fuer Infektionsforschung | Medicament for treatment of liver cancer |
| WO2013019975A1 (en) | 2011-08-03 | 2013-02-07 | University Of Iowa Research Foundation | Compositions and methods of treating cancer |
| WO2013024467A2 (en) | 2011-08-18 | 2013-02-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Mitochondrial ribosomal proteins as aging regulators |
| US9765063B2 (en) * | 2011-09-09 | 2017-09-19 | New York University | Amido compounds as RORγt modulators and uses thereof |
| WO2013040206A1 (en) | 2011-09-14 | 2013-03-21 | Lewis Thomas J | Novel formulations comprising macrolide and tetracycline and their uses |
| WO2013130968A1 (en) | 2012-03-01 | 2013-09-06 | University Of Cincinnati | Ros-activated compounds as selective anti-cancer therapeutics |
| US9526795B2 (en) | 2012-08-28 | 2016-12-27 | Annam Biosciences, Llc | N-BOC-dendrimers and their conjugates |
| US20150224169A1 (en) | 2012-09-06 | 2015-08-13 | Mcmaster University | Compounds and methods for selectively targeting cancer stem cells |
| US20140106004A1 (en) | 2012-10-12 | 2014-04-17 | Bing Lou Wong | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
| US9636329B2 (en) | 2012-11-06 | 2017-05-02 | Northwestern University | Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors |
| US9937161B2 (en) | 2013-03-06 | 2018-04-10 | The General Hospital Corporation | Combinatorial compositions and methods for treatment of melanoma |
| US8728546B1 (en) * | 2013-03-15 | 2014-05-20 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer, cardiovascular diseases and inflammation |
| WO2015002996A1 (en) | 2013-07-01 | 2015-01-08 | University Of Georgia Research Foundation, Inc. | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy |
| US20150231069A1 (en) | 2014-02-20 | 2015-08-20 | Pankaj Modi | Oral formulations of chemotherapeutic agents |
| WO2015191668A1 (en) | 2014-06-10 | 2015-12-17 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid |
| GB201414806D0 (en) | 2014-08-20 | 2014-10-01 | Ucl Business Plc | Cyclosporin conjugates |
| US10413558B2 (en) | 2014-10-17 | 2019-09-17 | Targeted Therapies Research And Consulting Center Sprl | Multi-ingredient pharmaceutical composition for use in cancer therapy |
| JP6439931B2 (ja) | 2015-02-26 | 2018-12-19 | 大日本印刷株式会社 | 吸着搬送装置および吸着搬送方法 |
| HK1259342A1 (zh) | 2015-10-06 | 2019-11-29 | Redhill Biopharma Ltd. | 用於治疗癌症的联合疗法 |
| JP2019528689A (ja) | 2016-08-11 | 2019-10-17 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | 免疫調節化合物 |
| EP3570857A1 (en) | 2017-01-18 | 2019-11-27 | Evelo Biosciences, Inc. | Methods of treating cancer |
| US20200121739A1 (en) | 2017-01-18 | 2020-04-23 | Evelo Biosciences, Inc. | Bacteria for treating cancer |
| US11197872B2 (en) | 2017-04-21 | 2021-12-14 | Lunella Biotech, Inc. | Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs) |
| EP3612177A4 (en) | 2017-04-21 | 2021-01-13 | Lunella Biotech, Inc. | TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY |
| WO2018202910A1 (en) | 2017-05-05 | 2018-11-08 | Fondazione Istituto Italiano Di Tecnologia | Combination of antibiotic and bcl-2 inhibitor and uses thereof |
| WO2018213764A1 (en) | 2017-05-19 | 2018-11-22 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| CN111315400A (zh) | 2017-05-19 | 2020-06-19 | 卢内拉生物技术有限公司 | Antimitoscin：用于根除癌症干细胞的线粒体生物发生的靶向抑制剂 |
| WO2018218242A1 (en) | 2017-05-26 | 2018-11-29 | Epicentrx, Inc. | Methods and compositions for combination therapy |
| CA3064452A1 (en) * | 2017-06-26 | 2019-01-03 | Lunella Biotech, Inc. | Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells |
-
2018
- 2018-06-25 CA CA3064452A patent/CA3064452A1/en active Pending
- 2018-06-25 US US16/626,426 patent/US11667639B2/en active Active
- 2018-06-25 PE PE2019002554A patent/PE20200295A1/es unknown
- 2018-06-25 WO PCT/US2018/039354 patent/WO2019005698A1/en not_active Ceased
- 2018-06-25 RU RU2020102908A patent/RU2020102908A/ru unknown
- 2018-06-25 AU AU2018292283A patent/AU2018292283B2/en active Active
- 2018-06-25 MX MX2019014806A patent/MX2019014806A/es unknown
- 2018-06-25 EP EP18822701.1A patent/EP3644988B1/en active Active
- 2018-06-25 CN CN201880042546.XA patent/CN110913854B/zh active Active
- 2018-06-25 KR KR1020207001405A patent/KR102646172B1/ko active Active
- 2018-06-25 SG SG11201913134UA patent/SG11201913134UA/en unknown
- 2018-06-25 IL IL292109A patent/IL292109B2/en unknown
- 2018-06-25 PE PE2024001838A patent/PE20242070A1/es unknown
- 2018-06-25 CR CR20200033A patent/CR20200033A/es unknown
- 2018-06-25 CU CU2019000106A patent/CU20190106A7/es unknown
- 2018-06-25 KR KR1020247007593A patent/KR102854338B1/ko active Active
- 2018-06-25 JP JP2019570935A patent/JP7397672B2/ja active Active
-
2019
- 2019-11-20 IL IL270774A patent/IL270774A/en unknown
- 2019-11-26 ZA ZA2019/07831A patent/ZA201907831B/en unknown
- 2019-12-17 CL CL2019003708A patent/CL2019003708A1/es unknown
- 2019-12-17 CO CONC2019/0014259A patent/CO2019014259A2/es unknown
- 2019-12-19 DO DO2019000312A patent/DOP2019000312A/es unknown
- 2019-12-20 PH PH12019502892A patent/PH12019502892A1/en unknown
-
2020
- 2020-01-10 EC ECSENADI20201729A patent/ECSP20001729A/es unknown
- 2020-02-27 US US16/803,628 patent/US11667640B2/en active Active
- 2020-10-23 AU AU2020257159A patent/AU2020257159B2/en active Active
-
2021
- 2021-03-24 ZA ZA2021/01954A patent/ZA202101954B/en unknown
-
2022
- 2022-07-06 DO DO2022000142A patent/DOP2022000142A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502892A1 (en) | Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells | |
| ZA202203603B (en) | Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast | |
| PH12017501757A1 (en) | A novel paenibacillus strain, antifungal compounds, and methods for their use | |
| ZA201802331B (en) | Stable inoculant compositions and methods for producing same | |
| PH12020550476A1 (en) | Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (cscs) by inhibiting mitochondrial respiration | |
| MX2019010039A (es) | Composiciones y métodos para transducción de tumores. | |
| MY188541A (en) | Besifloxacin for the treatment of resistant acne | |
| MY203474A (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| PH12019501292A1 (en) | Pharmaceutical composition for preventing or treating cancer, comprising tetraarsenic hexoxide crystalline polymorph | |
| BR112016012870A8 (pt) | composições e métodos para melhorar a produção de alface | |
| BR112015018783A2 (pt) | mistura íntima seca, composição, método de preparação de uma mistura íntima seca e método de aumento da germinação, crescimento, metabolismo e/ou atividade enzimática de esporos bacterianos | |
| MY182946A (en) | Production of organic acids by fermentation at low ph | |
| WO2017155942A3 (en) | Substituted heterocycles as c-myc targeting agents | |
| BR112019000837A2 (pt) | células miméticas de célula b | |
| MX2010007810A (es) | Coposicion que contiene capsicum para tratar un trastorno de la piel. | |
| GEAP201914591A (en) | Histamine-producing bacterial strains and their use in cancer | |
| WO2019035089A3 (en) | Lectin-bound bacteria and uses thereof | |
| MX2017000184A (es) | Agentes de interaccion enzimatica. | |
| Breid et al. | Erratum: Postadiabatic Hamiltonian for low-energy excitations in a slowly-time-dependent BCS-BEC crossover [Phys. Rev. A 88, 033617 (2013)] | |
| PH12016502133A1 (en) | Substituted tricycle compounds as fgfr inhibitors |